Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
| ▸ | AHCY | P23526 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7911779 | 0.81 | DYRK1A (0.42) | DYRK1ASCN2ACYP3A4PLAUHTT | |
| SCHEMBL4596087 | 0.79 | DYRK1A (0.41) | DYRK1ASCN2AALDH1A1CYP3A4PLAU | |
| SCHEMBL4375909 | 0.79 | DYRK1A (0.32) | DYRK1AALDH1A1CYP3A4PLAUHTT | |
| SCHEMBL29365456 | 0.75 | DYRK1A (0.31) | DYRK1A | |
| SCHEMBL11610661 | 0.75 | PLAU (0.33) | DYRK1APLAU | |
| SCHEMBL2223631 | 0.75 | PLAU (0.50) | DYRK1ASCN2AALDH1A1PLAUKMT2A | |
| SCHEMBL29142223 | 0.75 | DYRK1A (0.38) | DYRK1A | |
| SCHEMBL17670982 | 0.75 | PLAU (0.37) | DYRK1APLAUKMT2ANOS3NOS1 | |
| SCHEMBL22831886 | 0.75 | DYRK1A (0.38) | DYRK1ASCN2A | |
| SCHEMBL29509758 | 0.75 | DYRK1A (0.38) | DYRK1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701635-B2 | C-H fluorination of heterocycles with silver (II) fluoride | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160185723-A1 | C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-30 | — | — | US | disclosed |
| WO-2015013715-A2 | C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE | THR REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-01-29 | — | — | WO | disclosed |
| EP-0901482-A1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | Darwin Discovery Limited (GB) | 1999-03-17 | — | — | EP | disclosed |
| EP-0873331-A1 | BENZOFURAN CARBOXAMIDES AND SULPHONAMIDES | Darwin Discovery Limited (GB) | 1998-10-28 | — | — | EP | disclosed |
| US-5773467-A | Benzofuran sulphonanmides | CHIROSCIENCE, LTD. (GB) | 1998-06-30 | — | — | US | disclosed |
| EP-0741707-B1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE POULENC RORER LTD (GB) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997044337-A1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LIMITED (GB) | 1997-11-27 | — | — | WO | disclosed |
| WO-1997020833-A1 | BENZOFURAN CARBOXAMIDES AND SULPHONAMIDES | DARWIN DISCOVERY LIMITED (GB) | 1997-06-12 | — | — | WO | disclosed |
| EP-0741707-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995020578-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185723-A1 | C-H FLUORINATION OF HETEROCYCLES WITH SILVER (II) FLUORIDE | AFF2, INF2, NPFFR2 | DYRK1A 1206/4885SCN2A 419/4885ALDH1A1 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.